N-heterocyclic inhibitors of TNF-α expression

A compound of Formula I, and an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof

• wherein:
• V is —CHR5— or —NR5;
• two of W, X, and Y are each —N═ and the other is —CH═;
• Z is —N(R1)(R2), —S-aryl or S-substituted aryl;
• —N(R1)(R2) taken together may form a heterocyclyl or substituted heterocyclyl or R1 and R2 are selected as
• is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
• R5 is hydrogen;
• R6 is
• R7 is hydrogen, alkyl, substituted alkyl, alkoxy or halogen;
• R8 is hydrogen;
• R9 is —C(O)R10, heterocyclyl or substituted heterocyclyl;
• R10 is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl or —N(R31)(R32);
• R31 is hydrogen, alkyl or substituted alkyl;
• R32 is hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
• R11 is —N(R12)(R13);
• R12 is hydrogen, alkyl or substituted alkyl;
• R13 is —(CH2)mR14;
• or
• —N(R12)(R13) taken together form a heterocyclyl or substituted heterocyclyl;
• m is 0, 1, 2 or 3;
• R14 is hydrogen, alkyl, substituted alkyl, —C(O)N(R31)(R32), —N(R33)C(O)R34, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl or
• R15 is hydrogen, alkyl or substituted alkyl;
• R16 is hydrogen or alkyl;
• R33 is hydrogen, alkyl or substituted alkyl;
• and
• R34 is alkyl, substituted alkyl, aryl or substituted aryl.